Tarsus Pharmaceuticals, Inc.
TARS
Pozycja w akcjach
#4603
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Cena akcji
$71.00
Kapitalizacja rynkowa
$3.32B
Zmiana (1 dzień)
2.16%
Zmiana (1 rok)
-0.26%
Kraj
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Kategoria
Healthcare
Zyski dla Tarsus Pharmaceuticals, Inc. (TARS)
Zyski w Jun 2026 TTM: $-44.05M
Według najnowszych raportów finansowych Tarsus Pharmaceuticals, Inc., obecny zysk firmy wynosi $-44.05M. W roku 2023 firma osiągnęła zysk w wysokości $-135.89M, spadek w porównaniu do zysku z roku 2022, który wynosił $-62.10M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Tarsus Pharmaceuticals, Inc. od 2018 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $-44.05M | -61.88% |
| 2024 | $-115.55M | -14.97% |
| 2023 | $-135.89M | 118.85% |
| 2022 | $-62.10M | 350.88% |
| 2021 | $-13.77M | -48.63% |
| 2020 | $-26.81M | 474.21% |
| 2019 | $-4.67M | 254.25% |
| 2018 | $-1.32M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | -12,073.99% |
US
|
|
| $-3.09B | 6,907.47% |
US
|
|
| $-4.02B | 9,016.74% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -4,527.96% |
NL
|
